Abivax
ABVX
ATLANTA, GA – – (Globe Newswire – November 20, 2026) – – Holzer & Holzer, LLC is investigating whether Abivax S.A. (“Abivax” or the “Company”) (NASDAQ: ABVX) complied with federal securities laws. On November 18, 2026, Scorpion Capital published a report alleging, among other things, that obefazimod exhibits high lipophilicity, “violates one of the industry’s most basic screens for oral drug viability” and further alleges that the drug’s properties “resembles the signature of persistent organic pollutants (POPs) and certain agrochemicals.” On this news, the price of the Company’s stock dropped.
If you purchased Abivax stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/abivax/ to discuss your legal rights.
Registration Deadline